StockDuty ← Dashboard Nov 15, 2026 05:44 PM ET
SignalFDA/Bio

The FDA declined to approve Summit's lung cancer drug after the trial missed a key survival goal. That is the binary risk in the equity, and no approval leaves the story trading on a missed endpoint,

FDA declined approval after the drug missed a key survival goal.

SMMT
$11.82
-16.47%
FDA declined approval after the drug missed a key survival goal.
FDA declined approval after the drug missed a key survival goal. — impact context not separately stored; see What changed.
Sources